This federal contract award is for the delivery of the radiopharmaceutical PLUVICTO to the Cleveland VA Medical Center (VAMC). The $598,124.52 firm fixed price delivery order was issued against Novartis Pharmaceuticals Corporation's Federal Supply Schedule (FSS) contract for pharmaceuticals and drugs (FSS-61-IB). Novartis, a foreign-owned for-profit manufacturer, has provided specialized cancer therapies like Kymriah to VA networks and facilities under previous orders and agreements. This order does not have a set-aside designation, allowing the VA to procure the medication directly through Novartis' established FSS contract to facilitate treatment for veterans. The contract has an ultimate completion date of August 31, 2025.
Generated 2/7/25, 9:08 AM